14:01:27 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
DanCann Pharma grundades 2018 och är ett danskt läkemedelsbioteknikbolag som drivs av cannabinoider. DanCann Pharma fokuserar på att upptäcka, utveckla, tillverka och kommersialisera nya cannabinoida läkemedel inom ett brett spektrum av sjukdomsområden. Bolaget tillverkar och distribuerar receptbelagda läkemedel och receptfria läkemedel (OTC), främst fokuserade på smärtpatienter med alternativa behov och hantering av sin sjukdom, täckta av det danska pilotprogrammet för medicinsk cannabis.

Kalender

2022-04-07 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-07-23 Extra Bolagsstämma 2021
2021-05-28 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning DANCAN 0.00 DKK
2021-04-28 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2021-05-26 09:13:25

COPENHAGEN, Denmark, 26 May 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby happily announce that the Danish government with the support from other political parties have entered into an agreement on 25 May 2021 to continue the The Pilot Programme with medical cannabis.

It has been agreed that the Pilot Programme for medical cannabis will be extended for another four years as regards the possibility for doctors to prescribe medical cannabis to patients. Furthermore, it has been agreed that the Pilot Programme will be made permanent with regard to the possibility for companies to manufacture cannabis for medical use. The purpose of making the cultivation part permanent is to create clarification and security for the investments made in the industry.

The parties have agreed to discuss potential changes to the scheme, e.g., subsidies in the autumn. The parties have also agreed that adjustments to the program may be made at a later date. The parties have decided to discuss a continuation of subsidies for patients for the purchase of medical cannabis in the Pilot Programme this autumn.

The current Pilot Programme for medical cannabis will expire at the end of 2021, and the continuation of the Pilot Programme must therefore take place by law. The government will present a bill in the autumn of 2021 with a view to its adoption before the end of 2021. The parties to the agreement have agreed to vote in favor of the bill. In connection with the bill process, minor technical adjustments may be made to the program.

The decision makes Danish cultivation and production of medical cannabis permanent beyond the expiration of the current Pilot Programme in end-December 2021. With this decision, Denmark formally continues its ambition to become a leading player in the field of medical cannabis with an intention to serve both the home market and international markets.

The decision extends the Pilot Programme for prescription of medical cannabis with another four years, when the current Pilot Programme expires end-December 2021. This will allow all doctors to continue prescribing medical cannabis products to their patients regardless of illness (i.e., indication). The agreement also outlines, that the Danish parliament will debate the levels of patient cost coverage or refund during the Autumn assembly.CEO of DanCann Pharma, Jeppe Krog Rasmussen, comments:

"The Pilot Programme has been made a permanent scheme for manufacturers and added another 4 years to the scheme for patients. Perhaps the biggest risk associated with our business and our basis of existence is now eliminated? A great victory for us as a company and for our investors. A big, big day in terms of this, and quite a historical day, I would say.

We applause the Danish Parliament's decision to extend the Pilot Programme that allow local cultivation and production of medical cannabis. The overall agreement is good news for the entire Danish medical cannabis industry and ecosystem as it is likely to attract further investments and stimulate the drive towards making Denmark a leading nation within the field of medical cannabis. Now the industry - and we as a Company - can calm down and start creating further investments, development, and earnings.

This is a significant step. I am very happy and satisfied. I feel that we have helped and pushed to make a difference in order to get this in place. We can be proud of that and ourselves.

With that said, we must not forget our Danish patients, despite another 4-year trial period with the prescription of medical cannabis in Denmark, nothing has changed in the legal framework regarding conditions, this is just not good enough. We will continue to fight for this as always and we will demand better conditions as well. Hopefully we can address this in the autumn, we must not forget what this is all about, namely the patients.

Thank you very much to all the politicians, NGO's and other stakeholders, who have made a great effort to make this happen, and to continue the medical cannabis industry on a permanent basis. Congratulations to everybody involved."
 

Source: https://sum.dk/nyheder/2021/maj/forsoegsordningen-for-medicinsk-cannabis-viderefoeres

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com